企業一覧に戻る

NORDSON CORPNDSN)の決算・業績分析

NORDSON CORPの2025年有価証券報告書をAI分析。売上高$2.8B(+3.8%)。営業利益$712M。Industrials

目次
SUMMARY — 業績サマリー

NORDSON CORP2025年度 業績サマリー

NORDSON CORP(証券コード: NDSN)の2025年度決算・業績分析。売上高は$2.8B(前年比+3.8%)。営業利益は$712M(前年比+5.6%)。純利益は$484M(前年比+3.7%)。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。

NORDSON CORP2024年度 注目ポイント

※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。

  1. Revenue grew 9.7% YoY to $2.6B (XBRL), driven by strong demand in key end markets.
  2. Operating income surged 14.2% YoY to $702M (XBRL), with operating margin expanding to 27.1% (XBRL).
  3. Net income increased 12.9% YoY to $513M (XBRL), reflecting improved profitability and cost management.
  4. Shareholders received $389M in returns via dividends ($126M) and share repurchases ($263M) (XBRL).
  5. ROE reached 19.8% (XBRL), supported by strong equity growth and efficient capital allocation.

NORDSON CORPの売上高変化の要因

  • Total revenue reached $2.6B (XBRL), a 9.7% YoY increase. No segment or product line revenue breakdown is available in the provided data (XBRL). Growth drivers are not explicitly detailed, but the company attributes performance to its differentiated products and systems (10-K). Historical revenue trends show a 5-year CAGR of 3.1% (XBRL), with FY2024 marking the highest revenue level since FY2020.

NORDSON CORPの営業利益変化の要因

  • Operating income rose 14.2% YoY to $702M (XBRL), with operating margin expanding to 27.1% (XBRL). Net income increased 12.9% YoY to $513M (XBRL), translating to a net margin of 19.8% (XBRL). EBITDA reached $802M (31.0% of revenue) (XBRL). Gross profit data is not reported (N/A). R&D expenses were $53M (XBRL), though YoY changes are not specified. SG&A expenses are not disclosed (N/A).

NORDSON CORPの事業リスクと対応

Economic downturns or trade tensions could reduce revenue and profitability (10-K).

Currency fluctuations (euro, yen, etc.) may harm competitiveness and cost control (10-K).

Cyclical industries (electronics, polymer processing) are sensitive to economic shifts (10-K).

Geopolitical conflicts (Europe, Middle East) disrupt trade and markets (10-K).

Uncertainty in U.S. trade policy (tariffs, agreements) impacts operations and costs (10-K).

Trade restrictions may enable competitors to enter markets (10-K).

NORDSON CORPの今後の見通し・業績予想

No forward-looking guidance or management expectations for FY2025 are provided in the data (10-K). Key trends impacting future results are not explicitly detailed in the provided text (10-K).

NORDSON CORPの事業内容

Nordson Corp is a precision technology company engineering, manufacturing, and marketing products for dispensing, applying, and controlling fluids, as well as testing and treating surfaces (10-K). Key products include precision dispensing systems, surface treatment technologies, and medical components (catheters, cannulas, etc.) (10-K). The company serves diverse end markets such as packaging, electronics, medical, and energy (10-K). Competitive advantages include the NBS Next growth framework, Owner Mindset organizational structure, and Winning Teams talent strategy (10-K). The company employs approximately 8,000 employees globally (10-K) with no significant workforce changes noted.

NORDSON CORPのAI業績分析レポート(2024年度)

NORDSON CORP (NDSN) FY2024 Annual Report Analysis

Highlights

Revenue grew 9.7% YoY to $2.6B (XBRL), with operating income rising 14.2% to $702M (XBRL).
Net income increased 12.9% YoY to $513M (XBRL), translating to a net margin of 19.8% (XBRL).
Shareholders received $389M in returns via dividends ($126M) and share repurchases ($263M) (XBRL).
ROE reached 19.8% (XBRL), supported by strong equity growth and efficient capital allocation.
Cash conversion cycle (CCC) was 111 days (XBRL), with receivables days at 1 day (XBRL) and inventory days at 143 days (XBRL).

Business Overview

Nordson Corp is a precision technology company engineering, manufacturing, and marketing products for dispensing, applying, and controlling fluids, as well as testing and treating surfaces (10-K). Key products include precision dispensing systems, surface treatment technologies, and medical components (catheters, cannulas, etc.) (10-K). The company serves diverse end markets such as packaging, electronics, medical, and energy (10-K). Competitive advantages include the NBS Next growth framework, Owner Mindset organizational structure, and Winning Teams talent strategy (10-K). The company employs approximately 8,000 employees globally (10-K) with no significant workforce changes noted.

Revenue Analysis

Total revenue reached $2.6B (XBRL), a 9.7% YoY increase. No segment or product line revenue breakdown is available in the provided data (XBRL). Growth drivers are not explicitly detailed, but the company attributes performance to its differentiated products and systems (10-K). Historical revenue trends show a 5-year CAGR of 3.1% (XBRL), with FY2024 marking the highest revenue level since FY2020.

Profitability Analysis

Operating income rose 14.2% YoY to $702M (XBRL), with operating margin expanding to 27.1% (XBRL). Net income increased 12.9% YoY to $513M (XBRL), translating to a net margin of 19.8% (XBRL). EBITDA reached $802M (31.0% of revenue) (XBRL). Gross profit data is not reported (N/A). R&D expenses were $53M (XBRL), though YoY changes are not specified. SG&A expenses are not disclosed (N/A).

Balance Sheet Analysis

Equity grew to $2.6B (XBRL), with an equity ratio of 68.0% (XBRL). Total assets reached $3.8B (XBRL), while total liabilities include $1.6B in long-term debt (XBRL). Net debt stood at $1.5B (1.9x EBITDA) (XBRL). Current ratio was 2.11x (XBRL), indicating strong liquidity. Cash balances were $116M (XBRL). No details on debt maturity schedules or interest rates are provided (N/A).

Cash Flow Analysis

Operating cash flow was $513M (XBRL), matching net income. Free cash flow (FCF) totaled $462M (XBRL), calculated as operating cash flow ($513M) minus CapEx ($51M) (XBRL). Investing activities included $-223M (XBRL), primarily driven by CapEx. Financing activities totaled $-416M (XBRL), reflecting $126M in dividends paid and $263M in share repurchases (XBRL).

Working Capital Analysis

Cash conversion cycle (CCC) was 111 days (XBRL), with receivables days at 1 day (XBRL), inventory days at 143 days (XBRL), and payables days at 33 days (XBRL). Asset turnover was 0.68x (XBRL), indicating moderate efficiency in asset utilization.

Risks

Economic downturns or trade tensions could reduce revenue and profitability (10-K).
Currency fluctuations (euro, yen, etc.) may harm competitiveness and cost control (10-K).
Cyclical industries (electronics, polymer processing) are sensitive to economic shifts (10-K).
Geopolitical conflicts (Europe, Middle East) disrupt trade and markets (10-K).
Uncertainty in U.S. trade policy (tariffs, agreements) impacts operations and costs (10-K).
Trade restrictions may enable competitors to enter markets (10-K).

Outlook

No forward-looking guidance or management expectations for FY2025 are provided in the data (10-K). Key trends impacting future results are not explicitly detailed in the provided text (10-K).

Historical Time Series

MetricFY2020FY2021FY2022FY2023FY2024FY2025
Revenue2.3B2.2B2.1B2.4B2.6B2.6B
Operating Income503M483M350M615M702M673M
Net Income377M337M250M454M513M487M
Total Assets3.4B3.5B3.7B3.8B3.8B6.0B
Total Equity1.6B1.8B2.2B2.3B2.6B2.9B
Operating Cash Flow505M383M502M546M513M641M

Industrialsの企業一覧

NORDSON CORPと同じ「Industrials」セクターの企業